Compare GSK plc (GSK) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs MasterCard Inc — how do they compare? GSK plc trades at $46.43 (market cap $91.88B), while MasterCard Inc trades at $585.59 (market cap $503.50B). The key difference: MasterCard Inc is far larger — about 5.5× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and MasterCard Inc for 134 Days on average.
| GSK | MA | |
|---|---|---|
Market Cap | $91.88B | $503.50B |
Volume | 7,730,529 | 3,390,859 |
Sector | Health | Financials |
52-Week High | $61.18 | $599.86 |
52-Week Low | $43.24 | $471.55 |
Typical Hold Time | 93 Days | 134 Days |
Enterprise Value | $111.88B | $516.53B |
Dividend Yield | 3.9% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Mastercard (MA) trades at $570.06, up 0.61% with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $32.79B in 2025 with impressive 46.34% net margins, though valuation multiples remain elevated with P/E at 31.61. Recent institutional buying activity and positive analyst coverage support the upward trend.
Mastercard presents a compelling growth story with expanding global payment volumes and digital transformation initiatives. The primary investment thesis centers on continued market share gains and margin expansion, though risks include payment industry disruption from stablecoins and elevated valuation multiples requiring sustained high growth. Analyst consensus targets $666.67 suggest 17% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
